



an Open Access Journal by MDPI

Novel Targets for Fibrosis Development: Macrophages as a Source of Ligands and Myofibroblast Transition

Guest Editor:

Prof. Dr. Dolores Ortiz-Masiá

1. Departamento de Medicina,
Facultad de Medicina,
Universidad de Valencia, 46010
Valencia, Spain
2. Centro de Investigación
Biomédica en Red Enfermedades
Hepáticas y Digestivas
(CIBERehd), 46010 Valencia,
Spain

Deadline for manuscript
submissions:

closed (31 July 2022)

Message from the Guest Editor

Dear Colleagues,

Macrophages play an important role in the maintenance of tissue homeostasis; their reply to injury varies immensely depending on the nature and duration of the insult. In addition, recent studies demonstrate that macrophages can directly transform into myofibroblasts within the injured tissue. In this regard, therapeutic strategies aimed at controlling macrophage activation, polarization and transition should be emphasized in the prevention of fibrosis.

We cordially invite authors in the field to submit original research or review articles pertaining to this field of biomedicine.

Prof. Dr. Dolores Ortiz-Masiá
Guest Editor



mdpi.com/si/78539



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI